Voyager Therapeutics (NASDAQ:VYGR) Insider Todd Alfred Carter Sells 3,525 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) insider Todd Alfred Carter sold 3,525 shares of Voyager Therapeutics stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $3.85, for a total value of $13,571.25. Following the completion of the transaction, the insider directly owned 153,193 shares in the company, valued at approximately $589,793.05. This represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Voyager Therapeutics Stock Down 1.4%

Shares of VYGR stock traded down $0.05 during trading hours on Wednesday, reaching $3.65. 467,331 shares of the company’s stock were exchanged, compared to its average volume of 640,376. Voyager Therapeutics, Inc. has a fifty-two week low of $2.64 and a fifty-two week high of $5.55. The stock has a market capitalization of $202.94 million, a P/E ratio of -1.69 and a beta of 1.30. The business has a fifty day moving average price of $4.03 and a 200-day moving average price of $4.09.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Monday, November 10th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.06. The firm had revenue of $11.15 million during the quarter, compared to analysts’ expectations of $7.86 million. Voyager Therapeutics had a negative net margin of 404.85% and a negative return on equity of 48.94%. As a group, research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Analyst Ratings Changes

VYGR has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Wall Street Zen upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright reduced their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $13.75.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Privium Fund Management B.V. lifted its holdings in shares of Voyager Therapeutics by 16.6% during the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company’s stock valued at $79,000 after acquiring an additional 3,596 shares during the period. Allspring Global Investments Holdings LLC increased its position in shares of Voyager Therapeutics by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 61,775 shares of the company’s stock worth $249,000 after purchasing an additional 5,422 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Voyager Therapeutics by 1.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company’s stock worth $1,191,000 after purchasing an additional 5,560 shares in the last quarter. American Century Companies Inc. lifted its holdings in Voyager Therapeutics by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after purchasing an additional 6,748 shares during the last quarter. Finally, Jain Global LLC boosted its position in Voyager Therapeutics by 44.1% in the third quarter. Jain Global LLC now owns 28,104 shares of the company’s stock valued at $131,000 after buying an additional 8,600 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.